Sterling Madeline R, Durant Raegan W, Bryan Joanna, Levitan Emily B, Brown Todd M, Khodneva Yulia, Glasser Stephen P, Richman Joshua S, Howard George, Cushman Mary, Safford Monika M
Division of General Internal Medicine, Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, P.O. Box 46, New York, N.Y 10065, USA.
Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
BMC Cardiovasc Disord. 2018 Apr 16;18(1):66. doi: 10.1186/s12872-018-0806-4.
N-terminal pro B-type peptide (NT-proBNP) has been associated with risk of myocardial infarction (MI), but less is known about the relationship between NT-proBNP and very small non ST-elevation MI, also known as microsize MI. These events are now routinely detectable with modern troponin assays and are emerging as a large proportion of all MI. Here, we sought to compare the association of NT-proBNP with risk of incident typical MI and microsize MI in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
The REGARDS Study is a national cohort of 30,239 US community-dwelling black and white adults aged ≥ 45 years recruited from 2003 to 2007. Expert-adjudicated outcomes included incident typical MI (definite/probable MI with peak troponin ≥ 0.5 μg/L), incident microsize MI (definite/probable MI with peak troponin < 0.5 μg/L), and incident fatal CHD. Using a case-cohort design, we estimated the hazard ratio of the outcomes as a function of baseline NT-proBNP. Competing risk analyses tested whether the associations of NT-proBNP differed between the risk of incident microsize MI and incident typical MI as well as if the association of NT-proBNP differed between incident non-fatal microsize MI and incident non-fatal typical MI, while accounting for incident fatal coronary heart disease (CHD) as well as heart failure (HF).
Over a median of 5 years of follow-up, there were 315 typical MI, 139 microsize MI, and 195 incident fatal CHD. NT-proBNP was independently and strongly associated with all CHD endpoints, with significantly greater risk observed for incident microsize MI, even after removing individuals with suspected HF prior to or coincident with their incident CHD event.
NT-proBNP is associated with all MIs, but is a more powerful risk factor for microsize than typical MI.
N 末端 B 型利钠肽原(NT-proBNP)与心肌梗死(MI)风险相关,但 NT-proBNP 与非常小的非 ST 段抬高型心肌梗死(也称为微小尺寸 MI)之间的关系鲜为人知。这些事件现在通过现代肌钙蛋白检测可常规检测到,并且在所有 MI 中占很大比例。在此,我们试图在中风地理和种族差异原因(REGARDS)研究中比较 NT-proBNP 与典型 MI 和微小尺寸 MI 发病风险的关联。
REGARDS 研究是一项全国性队列研究,纳入了 2003 年至 2007 年招募的 30239 名年龄≥45 岁的美国社区居住的黑人和白人成年人。专家判定的结局包括典型 MI 发病(肌钙蛋白峰值≥0.5μg/L 的确诊/疑似 MI)、微小尺寸 MI 发病(肌钙蛋白峰值<0.5μg/L 的确诊/疑似 MI)和致命性冠心病发病。采用病例队列设计,我们估计了结局的风险比作为基线 NT-proBNP 的函数。竞争风险分析测试了 NT-proBNP 在微小尺寸 MI 发病风险和典型 MI 发病风险之间的关联是否不同,以及 NT-proBNP 在非致命性微小尺寸 MI 发病和非致命性典型 MI 发病之间的关联是否不同,同时考虑了致命性冠心病(CHD)发病以及心力衰竭(HF)。
在中位 5 年的随访中,有 315 例典型 MI、139 例微小尺寸 MI 和 195 例致命性冠心病发病。NT-proBNP 与所有冠心病终点均独立且密切相关,即使在排除发病冠心病事件之前或同时患有疑似 HF 的个体后,微小尺寸 MI 发病的风险仍显著更高。
NT-proBNP 与所有心肌梗死相关,但对于微小尺寸 MI 而言,它是比典型 MI 更强的风险因素。